Eurobench.com

[verwijderd] 5 april 2020 09:00

0

[quote alias=Flatlander id=12291349 date=202004041904]
[...]

I tend to agree. At one point I think the assay development turnaround time may have been shorter at BCART, based on the Emergency Use Ebola cartridge released in 2016. However, this may have provided BCART a valuable lesson that it wasn't worth chasing infectious disease outbreaks. I doubt that they ever recouped the investment or got that much name recognition from the effort.

That said, I suspect that ImmunExpress is pressing the FDA for expedited approval of Septicyte Rapid for use in Triaging patients. Based on news flow it seems like the FDA is approving several COVID 19 related tests per week.

FL
[/qu
ote]
Een versnelde goedkeuring van de FDA zou natuurlijk ook zeer mooi en relevant zijn.Het zou ook een enorme trigger zijn om de koers van Biocartis een opstoot te geven,en zodoende die shorters voorgoed het zwijgen op te leggen.

[verwijderd] 5 april 2020 18:05

0

Het coronavirus brengt de ziekenhuizen in grote financiële problemen, zonder dat er buffers zijn om de schok op te vangen.

www.tijd.be/politiek-economie/belgie/...

Flatlander 6 april 2020 14:50

0

Insider Buying?
Section 4 of the Annual Report identifies the number of shares held by various executive team members. It appears that many of the shares (for instance granted to Board members) were acquired via options from BCART as part of the remuneration program that have vested. Verrelst has 1.2 million shares. Were any of these shares purchased recently on the open market? Does anyone have a link to a site (similar to the SEC.gov) that tracks insider activity on the Brussels listed equities? It seems at the present SP, insider buying would help portray that management is confident in the magnitude of the 2021 acceleration.

Thanks
FL

CGCDLR 6 april 2020 16:08

0

Verrelst verkreeg 2x670000 0pties/warrants in het kader van verloningsbeleid Biocartis.Melding fsma 16/10/2017

[verwijderd] 6 april 2020 16:15

0

quote:
Flatlander schreef op 6 april 2020 14:50:
Insider Buying?
Section 4 of the Annual Report identifies the number of shares held by various executive team members. It appears that many of the shares (for instance granted to Board members) were acquired via options from BCART as part of the remuneration program that have vested. Verrelst has 1.2 million shares. Were any of these shares purchased recently on the open market? Does anyone have a link to a site (similar to the SEC.gov) that tracks insider activity on the Brussels listed equities? It seems at the present SP, insider buying would help portray that management is confident in the magnitude of the 2021 acceleration.

Thanks

https://www.fsma.be/nl/transaction-search?field_issuer_tid=6974&submit=Zoeken

stori.fsma.be/Pages/Search.aspx?PageI...

brightlight 6 april 2020 17:44

0

quote:
Flatlander schreef op 6 april 2020 14:50:
... insider buying would help portray that management is confident in the magnitude of the 2021 acceleration.

Thanks
FL

FL
what order of magnitude would a 2021 acceleration look like, in your opinion? 400,000 cartridges sold, or more? or less?
BL

[verwijderd] 6 april 2020 20:24

0

Personally I think Biocartis should invest in its infectious disease pipeline. However it should be part of a solid marketing strategy and not based on opportunities. The Ebola test was driven by Rudi Pauwels who has written history before Tibotec was bought by JNJ. It did generate sales but the critical mass in assays was to small. But where do you start. BCART doesn’t have unlimited resources.

But think about what Idylla can offer if you would decentralize the triage and create an international diagnostic grid. Anonymus for all I care, but real-time. I can assure you with the precision PCR can offer, the ease of use of Idylla and the idea of creating a 2.0 GP ... you would solve a lot of challenges we are facing today. And although Covid-19 already is a dangerous virus due to various reasons, it can be worse.

I think this event should make policy makers and health care professionals re-think about the value of testing.

Everybody is focusing on oncology because that sounds sexy to a lot of institutional investors, but please do not forget infectious diseases. I think the latest developments & partnerships are promising for a bright future for Biocartis! They should pick a fight with the big suppliers of central labs, but re-invent the model of diagnostic testing and monitoring. And a well trained GP can do so much more than just ‘guessing’ with the right tools.

Keep safe!

[verwijderd] 7 april 2020 09:02

0

Vandaag nieuwe vacature: Senior scientist.

euroke 7 april 2020 12:18

0

Er staat nog heel wat open bij Biocartis.
www.linkedin.com/company/biocartis/

[verwijderd] 7 april 2020 12:28

0

Een TOP financiele directeur is natuurlijk prioriteit voor ons.

Bruyne 7 april 2020 12:48

0

Zo, gisteren ingestapt. De weg naar 4Eur lijkt ingeslagen, kunnen we eens een Pharnext dagje meemaken?

Flatlander 7 april 2020 17:54

0

quote:
M /// schreef op 6 april 2020 20:24:
Personally I think Biocartis should invest in its infectious disease pipeline. However it should be part of a solid marketing strategy and not based on opportunities. The Ebola test was driven by Rudi Pauwels who has written history before Tibotec was bought by JNJ. It did generate sales but the critical mass in assays was to small. But where do you start. BCART doesn’t have unlimited resources.

But think about what Idylla can offer if you would decentralize the triage and create an international diagnostic grid. Anonymus for all I care, but real-time. I can assure you with the precision PCR can offer, the ease of use of Idylla and the idea of creating a 2.0 GP ... you would solve a lot of challenges we are facing today. And although Covid-19 already is a dangerous virus due to various reasons, it can be worse.

I think this event should make policy makers and health care professionals re-think about the value of testing.

Everybody is focusing on oncology because that sounds sexy to a lot of institutional investors, but please do not forget infectious diseases. I think the latest developments & partnerships are promising for a bright future for Biocartis! They should pick a fight with the big suppliers of central labs, but re-invent the model of diagnostic testing and monitoring. And a well trained GP can do so much more than just ‘guessing’ with the right tools.

Keep safe!

M
Infectious disease is pretty crowded, and there are several point of care systems that BCART would have to compete head to head with (Cepheids GenExpert, Abbot's ID Now or Alere, Biofire film array, Roche Molecular Systems, Qiagen, etc.). Alternatively, the Oncology Point of Care sample to answer market is currently wide open. Therefore, I think they are correct to focus on oncology. If a large partner (say Wonfu) wants to expend resources to develop infectious disease content to run on the Idylla platform, I think BCART should amend the partnership to allow them a greater portion of profits/royalties to cover their investment for that content. However, in the meantime I think BCART needs to maintain focus to conserve resources. Your point on "critical mass" is a good one. While partners have signed up to launch content on Idylla, EXAS has delayed recently in proceeding with OncoType Dx validation studies. Reportedly, they are assessing the go to market launch for the EU and ROW. It is quite possible that they are waiting to see more demonstration of console placements to resolve the critical mass issue. BCART is in a bit of "a chicken or the egg situation". They need good content to drive console placements and they need the console placements to make the platform more attractive to content partners. This is not unique in that Cepheid had a similar pace to their GenExpert system roll out. As we have pointed out, Cepheids growth has continued at better than 20% for more than a decade.

You seem to have a good understanding of BCART's history. That perspective is always needed. Welcome to the Board!

FL

Flatlander 7 april 2020 18:31

0

quote:
brightlight schreef op 6 april 2020 17:44:
[...]
FL
what order of magnitude would a 2021 acceleration look like, in your opinion? 400,000 cartridges sold, or more? or less?
BL

BL

With Coronavirus raging throughout the world, I think 2020 cartridges in the range of 230,000 would be an accomplishment. Assuming the virus is under control or management strategies are adopted that allow somewhat normal life activities, I'd look for at least 75% growth in 2021 (403,000). This is based on receipt of two diagnostic use approvals in the US and registration of some (MSI, KRAS, etc) content in Japan during the first half of 2021. Idylla has experienced growth spurts (70% or more) when they introduce the product as a RUO tool to a new geographic market. The diagnostic use designation would unlock the much bigger POC market resulting in more sustained cartridge use. China is a big variable. There has been little guidance on when sales would ramp there, so I have really not factored it in to any extent.

I first started investing in BCART feeling 2020 would be the year. Approvals and launches got pushed back, so I shifted to 2021 being the year. Now Coronavirus makes it more likely to be 2022 and beyond. Unfortunately, that probably means another round of financing before profitability. The market upheaval has created other opportunities, so I'm not adding to my BCART position. I'd like to see some insiders buying as a sign of better things to come. As I have said before, I'm committed to sticking it out through the POC introduction in the US and probably Asia. If it develops the kind of traction I believe it is capable of, it could be a great long term holding as the oncology MDx market will grow for decades. However, in the current market, BCART can only be viewed as a speculation at a time when the market is demanding sound balance sheets and proven market performance.

Regards FL

Flatlander 7 april 2020 18:37

0

Why hold a physical Annual Meeting in the current Coronavirus environment?

finance.yahoo.com/news/press-release-...

I think they should go with a virtual Annual meeting. I'm a shareholder in Alcon (spun out from Novartis) and they just announced there will be no physical meeting.

FL

brightlight 7 april 2020 20:58

0

quote:
Flatlander schreef op 7 april 2020 18:31:
[...]

BL

With Coronavirus raging throughout the world, I think 2020 cartridges in the range of 230,000 would be an accomplishment. Assuming the virus is under control or management strategies are adopted that allow somewhat normal life activities, I'd look for at least 75% growth in 2021 (403,000). This is based on receipt of two diagnostic use approvals in the US and registration of some (MSI, KRAS, etc) content in Japan during the first half of 2021. Idylla has experienced growth spurts (70% or more) when they introduce the product as a RUO tool to a new geographic market. The diagnostic use designation would unlock the much bigger POC market resulting in more sustained cartridge use. China is a big variable. There has been little guidance on when sales would ramp there, so I have really not factored it in to any extent..

Regards FL

FL
It is good to know we both see the 400,000 mark as not entirely unrealistic for 2021. I noticed the Wondfo-cartis website is already up and running with 9 tests on offer (RUO). I would suspect the same 9 tests will be offered in Japan, although Nichirei does not yet show any sign of Biocartis on their website. I suspect these will be the major growth drivers for this year, together with the Septicyte test: www.grandviewresearch.com/press-relea...
Concerning US diagnostic designation, as it now stands only one PMA will be submitted in Q4 2020 and 2 more in Q1 2021. And then there is the Septicyte US diagnostic designation which is expected in Q3 2020 if I am not mistaken. Whether the ramp up in 2021 can still happen will largely depend on how long the FDA will take to process the PMA's. I don't have the faintest idea about that. Also let's not forget Septicyte sales may surprise us in positive way for 2021.
BL

[verwijderd] 8 april 2020 09:39

0

Alweer 2 nieuwe vacatures.
Een Quality Assurance manager Development.
Een R&D Project Manager Product Development.
Er is blijkbaar veel beweging gaande daar in Mechelen.

[verwijderd] 8 april 2020 09:54

0

quote:
joe123 schreef op 8 april 2020 09:39:
Alweer 2 nieuwe vacatures.
Een Quality Assurance manager Development.
Een R&D Project Manager Product Development.
Er is blijkbaar veel beweging gaande daar in Mechelen.

Mooi als dat allemaal nieuwe vacatures zijn. Zou ook kunnen wijzen op heel veel verloop...
Moeten we dit als positief bekijken?
Anderzijds op paar dagen wel mooie opwaartse beweging. Zachtjes naar de 4 en daarna hopelijk 5 :)

[verwijderd] 8 april 2020 11:09

0

quote:
Nestel95 schreef op 8 april 2020 09:54:
[...]
Mooi als dat allemaal nieuwe vacatures zijn. Zou ook kunnen wijzen op heel veel verloop...
Moeten we dit als positief bekijken?
Anderzijds op paar dagen wel mooie opwaartse beweging. Zachtjes naar de 4 en daarna hopelijk 5 :)

Hopelijk snel maal drie.Dan zit ik terug aan mijn aankoopkoers en tevens introductiekoers van de beursgang van Biocrtis.Het was toen de beloftevolste beursintroductie van jaren.Ik heb er al veel geduld mee gehad,dus nog een jaar of vijf kan er nog wel bij.

[verwijderd] 8 april 2020 11:24

0

quote:
Rarezot schreef op 16 januari 2020 09:37:
[...]

Ja ik ben aandeelhouder. Ingestapt toen ik de technologie zag van de tweede lijn. Echt de meest impressionante lijn dat ik ooit aan heb gewerkt. Mijn aandeel is sterk vergroot na de dip, maar ik heb nog steeds verlies.

En ook de mentaliteit van de medewerkers was een van de beste dat ik al heb gezien. Tuurlijk waren er onderling soms wat wrijvingen, maar iedereen waar ik mee in contact kwam was zeer begaan met het bedrijf en erg gemotiveerd.

Het bedrijf heeft visie, ze werken er gezamelijk naartoe en het is een product waar ik achter sta.

Groeten,
Rarezot

[verwijderd] 8 april 2020 11:27

0

Hiermee is mijn mening dat het verloop wel zal meevallen.Wat Rarezot hierbij schrijft geeft mij veel vertrouwen.

Vertraagd	22 sep 2023
Koers	0,290
Verschil	0,000 (0,00%)
Hoog	0,000
Laag	0,000
Volume	0
Volume gemiddeld	0
Volume gisteren	112.228

Biocartis « Terug naar discussie overzicht

Biocartis forum geopend

Meedoen aan de discussie?

Direct naar Forum

Detail

Biocartis nieuws